Stealth Bio Posts Encouraging Preclinical Data In Parkinson's Animal Studies

Stealth BioTherapeutics Corp MITO has presented new data from a study evaluating SBT-272 in a murine model of Parkinson's disease (PD).
SBT-272 is a mitochondria-targeted product candidate, which is known to cross the blood-brain barrier.
The data were presented at the International Parkinson and Movement Disorder Society Virtual Congress 2021.
Systemic daily administration of SBT-272 at two doses significantly protected against the loss of dopaminergic neurons and the aggregation of pathological alpha-synuclein.
In addition, the higher dose of SBT-272 significantly reduced two different markers of neuroinflammation. Overall, the data demonstrate that SBT-272 has a neuroprotective effect in this model of PD.
In this study, systemic SBT-272 treatment protected brain mitochondria against damage caused by an ischemic stroke.
The Company plans to advance SBT-272 in dose-ranging Phase 1 studies early next year in addition to initiating chronic toxicology studies to support Phase 2 initiation.
Price Action: MITO stock is down 1.37% at $1.44 during the market session on the last check Thursday.